Neal K. Lakdawala

Neal K. Lakdawala

Cardiology
70 Francis Street
Carl J. And Ruth Shapiro Cardiovascular Center
Boston, MA 02115

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 177 publications

Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.

Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.

Journal: Circulation
Published: August 29, 2026

Damaging RBM20 E-rich domain variants are not rescued by gene replacement.

Damaging RBM20 E-rich domain variants are not rescued by gene replacement.

Journal: bioRxiv : the preprint server for biology
Published: July 29, 2026

Variant Site-Specific Natural History of Titin-Induced Cardiomyopathy: An International Multicenter Registry.

Variant Site-Specific Natural History of Titin-Induced Cardiomyopathy: An International Multicenter Registry.

Journal: Circulation. Genomic and precision medicine
Published: July 08, 2026

Correction to: The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis.

Correction to: The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis.

Journal: Circulation
Published: June 22, 2026

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial.

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial.

Journal: JAMA cardiology
Published: June 17, 2026

The Threshold for a Clinically Meaningful Improvement in Cardiopulmonary Exercise Testing Measures for Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy.

The Threshold for a Clinically Meaningful Improvement in Cardiopulmonary Exercise Testing Measures for Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy.

Journal: Journal of cardiac failure
Published: June 10, 2026

Efficacy of Aficamten vs Metoprolol According to Pretrial Beta-Blocker Treatment in Obstructive Hypertrophic Cardiomyopathy: Insights From MAPLE-HCM.

Efficacy of Aficamten vs Metoprolol According to Pretrial Beta-Blocker Treatment in Obstructive Hypertrophic Cardiomyopathy: Insights From MAPLE-HCM.

Journal: JACC. Heart failure
Published: June 08, 2026

Mavacamten monotherapy in obstructive hypertrophic cardiomyopathy: an integrated analysis of phase 3 clinical trials.

Mavacamten monotherapy in obstructive hypertrophic cardiomyopathy: an integrated analysis of phase 3 clinical trials.

Journal: American heart journal
Published: May 28, 2026

The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis.

The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis.

Journal: Circulation
Published: April 17, 2026

RBM20 Truncating Variants and Human Cardiomyopathy.

RBM20 Truncating Variants and Human Cardiomyopathy.

Journal: JAMA cardiology
Published: April 08, 2026

Truncating Variants in TTN are Associated With Primary Atrial Myopathy.

Truncating Variants in TTN are Associated With Primary Atrial Myopathy.

Journal: Journal of the American Heart Association
Published: March 10, 2026

Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy.

Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy.

Journal: Circulation
Published: March 09, 2026
Showing 1-12 of 177

Last Updated: 09/26/2026